The most telling detail about Rocket Lab’s current moment isn’t the number attached to any single analyst price target — it’s the contradiction embedded in the targets themselves. Two research houses cut their price objectives on the same day, yet neither touched its buy rating. That gap between lowered expectations and maintained conviction says more about where the stock stands than either metric alone.
Bank of America trimmed its target from $115 to $110 on September 1, while Roth Capital moved more aggressively, cutting from $130 to $110. Both kept their buy recommendations intact. Read the headlines and you see caution; read the ratings and you see something closer to recalibration — a resetting of near-term expectations rather than an abandonment of the underlying thesis.
A Launch Cadence That Keeps Delivering
The operational side of the business has shown no such hesitation. On September 2, Rocket Lab completed its 94th Electron launch — the 15th mission of 2026 — carrying a StriX Earth-observation satellite for Japanese customer Synspective. The flight extended a flawless track record with that payload partner, and media reports indicate Synspective has booked 16 additional launches through 2030, giving Rocket Lab rare multi-year revenue visibility in an industry where order books often stretch only a few quarters.
That same week brought a second mission, “Owl Around The World,” from Launch Complex 1 in New Zealand, delivering a payload to a 575-kilometer low Earth orbit. Two launches in quick succession for a company of this scale isn’t routine — it’s evidence of a well-oiled operational rhythm.
The NASA Setback That Stings
The smooth-growth narrative, however, has a visible crack. NASA awarded a Mars communications contract worth roughly $700 million not to Rocket Lab but to Blue Origin — a decision that lands awkwardly for a company positioning itself as a serious contender for deep-space missions. The loss signals that competition for the most lucrative government contracts is intensifying, particularly as more players bring their own launch vehicles and spacecraft to the table. In the new-space arena, a clean flight history alone no longer secures the marquee awards.
This competitive reality helps explain why analyst opinions have diverged. Berenberg initiated coverage on September 3 with a buy rating but a price target of just $83 — a stark contrast to the $110 targets from Bank of America and Roth Capital. Three houses, three different conclusions about fair value, all within days of each other.
Should investors sell immediately? Or is it worth buying Rocket Lab?
Institutions Vote With Their Wallets
Meanwhile, the capital flows tell their own story. ARK Invest purchased approximately 504,799 shares on September 2, valued at around $31.6 million — a position that sits uneasily alongside any bearish narrative. The Manufacturers Life Insurance Company also reported a new investment in the company, adding to the picture of institutional accumulation despite the stock’s volatility.
CFO Adam C. Spice sold 140,157 shares on September 2, though those sales followed the exercise of options and typically adhere to predetermined plans — transactions that say little about management’s view of future price action and shouldn’t be overinterpreted.
The Stock Tells a Different Story
The disconnect between operational substance and share price performance remains the central tension. The stock closed Friday at €55.50, up 1.1 percent on the day, but sits roughly 59 percent below its 52-week high of €133.80. Annualized volatility of 66 percent underscores just how jittery trading in this name has become. The relative strength index of 38.3 points to oversold conditions, though that alone doesn’t guarantee a reversal.
Neutron Remains the Wild Card
What gives investors more pause than the price target adjustments is the growing chatter around Neutron. Media reports suggest market participants are watching for a possible slip of the rocket’s first launch into 2027, with some hoping it still makes the window before year-end. No official company statement has addressed the timeline, but the mere existence of that concern reveals where the market locates Rocket Lab’s real growth story: not in the mature Electron franchise, but in the larger Neutron program. If that schedule remains uncertain, it will likely weigh on valuation more heavily than any adjustment to existing price targets.
Rocket Lab enters this stretch as a company operating on two tracks simultaneously — operationally on course with a dependable launch cadence and a deepening institutional footprint, yet strategically still in the proof stage. The coming months will test whether the company can translate its reliability in small-satellite launches into credibility for the big-ticket missions that define the sector’s top tier. The answer hinges less on analyst models than on whether Neutron holds its window.
Ad
Rocket Lab Stock: Buy or Sell?! New Rocket Lab Analysis from September 7 delivers the answer:
The latest Rocket Lab figures speak for themselves: Urgent action needed for Rocket Lab investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from September 7.
Rocket Lab: Buy or sell? Read more here...
